Pharmacological treatments of cerebellar ataxia

The Cerebellum
Masafumi Ogawa

Abstract

The confirmed pharmacological treatment of cerebellar ataxia is still lacking. In a recent preliminary trial, we showed that D-cycloserine, a partial NMDA allosteric agonist, may relieve the symptoms. In this paper, major clinical trials to relieve ataxic symptoms are reviewed. Previous studies showed some efficacy of physostigmine in ataxic patients. However, physostigmine did not improve the ataxia in a recent double-blind crossover study. The replacement therapy of the deficient cholinergic system with choline or choline derivatives was tried in patients with Friedreich's ataxia and other ataxic patients, but the result was not definitive. A levorotatory form of hydroxytryptophan (a serotonin precursor), a serotoninergic 5-HT1A agonist, a serotoninergic 5-HT3 antagonist, and a serotonin reuptake inhibitor were also used for the therapy for ataxia. In a double-blind randomized study, buspirone, a 5-HT1A agonist was active in cerebellar ataxia, but the effect is partial and not major. The effects of the studies with the other serotoninergic drugs were not consistent. The effect of sulfamethoxazole-trimethoprim therapy in spinocerebellar ataxia type3/Machado-Joseph disease (MJD) was reported, although the therapy improved spast...Continue Reading

Citations

Apr 18, 2008·The Cerebellum·Nobuyuki ShibusawaMasanobu Yamada
Jul 10, 2008·The Cerebellum·Noriyuki Koibuchi
Mar 27, 2012·The Cerebellum·Antoni Matilla-Dueñas
Jun 4, 2011·Orphanet Journal of Rare Diseases·Conceição Bettencourt, Manuela Lima
Jan 4, 2006·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Veronica F Colomer Gould
Dec 12, 2013·Computer Methods and Programs in Biomedicine·Samira AbbasiYashar Sarbaz
Aug 5, 2009·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Josef Finsterer
Oct 12, 2010·Behavioural Brain Research·Min ZhangLynne E Rueter
May 22, 2007·Journal of the Neurological Sciences·Mitra AssadiPaola Leone
Oct 28, 2008·Movement Disorders : Official Journal of the Movement Disorder Society·Joseph M FerraraWilliam G Ondo
Jun 1, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Thomas Klockgether, Henry Paulson
May 3, 2012·Journal of Child Neurology·Andreea NissenkornBruria Ben-Zeev
Jan 16, 2020·Journal of Neurology, Neurosurgery, and Psychiatry·Masatoyo NishizawaUNKNOWN Rovatirelin Study Group
Sep 24, 2020·Expert Opinion on Therapeutic Targets·Andreia Neves-CarvalhoPatrícia Maciel
May 22, 2021·Annals of Clinical and Translational Neurology·Sarah M BrookerPuneet Opal

❮ Previous
Next ❯

Related Concepts

Related Feeds

Ataxia telangiectasia (MDS)

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.

Ataxias

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on different types of ataxias here.

Ataxias (MDS)

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Ataxia

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.